Clinical Trials

ELIAS Animal Health has developed a unique immunotherapy treatment protocol which may permit the dog’s immune system to attack its own cancer cells. ELIAS Cancer Immunotherapy (ECI®)—a vaccine-enhanced adoptive cell therapy—has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment.

Canine Lymphoma

Pilot study evaluating the use of ECI in combination with chemotherapy to treat lymphoma in dogs.

Enrollment is on a limited basis.

Canine Osteosarcoma

Enrollment for the latest canine osteosarcoma clinical study (ECI-OSA-04) is now closed. Results will be available in 2023.

Find results of the pivotal study (ECI-OSA-01) here.

“The T cell expansion is a huge component that, to my knowledge, none of the other autologous products are even trying to replicate.”

Zachary Wright, DVM, DACVIM (Oncology)

VCA Animal Diagnostic Clinic